Skip to main content

REVIEW article

Front. Cell. Infect. Microbiol.
Sec. Intestinal Microbiome
Volume 14 - 2024 | doi: 10.3389/fcimb.2024.1450310
This article is part of the Research Topic Interaction of Microbiota and Metabolomic Disorders View all 6 articles

The gut microbiota: emerging biomarkers and potential treatments for infertility-related diseases

Provisionally accepted
Min Wang Min Wang 1Lianwen Zheng Lianwen Zheng 1Shuai Ma Shuai Ma 1Donghai Zhao Donghai Zhao 2*XU YING XU YING 1*
  • 1 Department of Obstetrics and Gynecology, Second Hospital of Jilin University, Changchun, China
  • 2 Jilin Medical University, Jilin, Jilin, China

The final, formatted version of the article will be published soon.

    Infertility is a disease of impaired fertility. With socioeconomic development, changes in human lifestyles, and increased environmental pollution, the problem of low human fertility has become increasingly prominent. The incidence of global infertility is increasing every year. Many factors lead to infertility, and common female factors include tubal factors, ovulation disorders, endometriosis, and immune factors. The gut microbiota is involved in many physiological processes, such as nutrient absorption, intestinal mucosal growth, glycolipid metabolism, and immune system regulation.An altered gut flora is associated with female infertility disorders such as polycystic ovary syndrome (PCOS), endometriosis (EMs), and premature ovarian failure (POF). Dysbiosis of the gut microbiota directly or indirectly contributes to the development of female infertility disorders, which also affect the homeostasis of the gut microbiota. Identifying the etiology and pathogenesis of infertility in patients is the focus of reproductive medicine physicians. We studied the developmental mechanism between the gut microbiota and PCOS, EMs, and POF from a new perspective, providing new ideas for diagnosing and treating female infertility diseases and specific reference values for eugenics.

    Keywords: Gut Microbiota, Infertility, Polycystic Ovary Syndrome, Endometriosis, premature ovarian failure, biomarkers, Therapeutics

    Received: 17 Jun 2024; Accepted: 03 Sep 2024.

    Copyright: © 2024 Wang, Zheng, Ma, Zhao and YING. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Donghai Zhao, Jilin Medical University, Jilin, Jilin, China
    XU YING, Department of Obstetrics and Gynecology, Second Hospital of Jilin University, Changchun, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.